


**Generation**<sup>®</sup>  
a new era in prenatal testing



**Generation**<sup>®</sup> Non-Invasive Prenatal Testing (NIPT) represents a major advance in screening and risk assessment for chromosomal abnormalities

- ✓ Lower Failure Rates – **Less than one patient per thousand tested (0.1%)\***
- ✓ Tested in Australia for fast turn around time
- ✓ Fetal fraction reported
- ✓ Includes optional genetic counselling support<sup>†</sup>
- ✓ Convenient collection through our extensive network

[laverty.com.au](http://laverty.com.au)

\* Based on internal testing data.

† For patients receiving an Aneuploidy Detected result from Generation testing.  
Specialist Diagnostic Services Pty Ltd ABN 84 007 190 043 APA No. 000042 trading as Laverty Pathology

  
**Genomic Diagnostics**  
LEADING THE WAY TO IMPROVE HEALTH

 **Laverty**<sup>®</sup>  
PATHOLOGY

RELIABLE	FAST	WHOLE GENOME SEQUENCING (WGS)	ACCURATE	CONVENIENT																					
<ul style="list-style-type: none"> <li>Get a result first time</li> </ul> <p><b>Our Experience</b></p> <p><b>&lt;0.1%</b></p> <p><b>Failure to report</b></p> <ul style="list-style-type: none"> <li>Less than one patient per thousand won't get a report</li> </ul>	<ul style="list-style-type: none"> <li>Tested in Australia for rapid turn around time</li> <li>Data analysis performed in Australia</li> </ul>	<ul style="list-style-type: none"> <li>WGS enables reporting at lower fetal fractions<sup>4</sup></li> <li>Enables an unbiased view and more reliable detection</li> </ul>	<ul style="list-style-type: none"> <li>High sensitivity rates achieved with Whole Genome Sequencing<sup>1,2,3</sup></li> </ul> <table border="1"> <thead> <tr> <th></th> <th>Observed Sensitivity</th> <th>Observed Specificity</th> </tr> </thead> <tbody> <tr> <td>Trisomy 21</td> <td>99.1%</td> <td>99.9%</td> </tr> <tr> <td>Trisomy 18</td> <td>98.3%</td> <td>99.9%</td> </tr> <tr> <td>Trisomy 13</td> <td>98.2%</td> <td>99.9%</td> </tr> <tr> <td>Monosomy X</td> <td>95.0%</td> <td>99.0%</td> </tr> <tr> <td>XX</td> <td>97.6%</td> <td>99.2%</td> </tr> <tr> <td>XY</td> <td>99.1%</td> <td>98.9%</td> </tr> </tbody> </table>		Observed Sensitivity	Observed Specificity	Trisomy 21	99.1%	99.9%	Trisomy 18	98.3%	99.9%	Trisomy 13	98.2%	99.9%	Monosomy X	95.0%	99.0%	XX	97.6%	99.2%	XY	99.1%	98.9%	<ul style="list-style-type: none"> <li>Collect from a wide range of centres – find one near you online: <a href="http://www.generationNIPT.com.au">www.generationNIPT.com.au</a></li> <li>Our customer care team are available Monday to Friday 9am - 5pm AEST</li> </ul> <p><b>1800 822 999</b></p>
	Observed Sensitivity	Observed Specificity																							
Trisomy 21	99.1%	99.9%																							
Trisomy 18	98.3%	99.9%																							
Trisomy 13	98.2%	99.9%																							
Monosomy X	95.0%	99.0%																							
XX	97.6%	99.2%																							
XY	99.1%	98.9%																							

### How to order:

- Complete the **Generation**<sup>®</sup> NIPT consent request form with your patient
- Your patient contacts our Customer Care Team on 1800 822 999 to prepay and identify the most conveniently located collection centres
- Once the **Generation**<sup>®</sup> NIPT is performed results can be downloaded or faxed.

### Further Information:

For more information on **Generation**<sup>®</sup> NIPT please visit [www.generationNIPT.com.au](http://www.generationNIPT.com.au) or call us on **1800 822 999**

The cost of **Generation**<sup>®</sup> NIPT is \$395 and is NOT Medicare rebatable. **Generation**<sup>®</sup> Plus NIPT for testing specific microdeletions is available as an additional option, where clinically indicated. Please contact us for further information and current pricing\*.

*\* Prices are correct at time of printing and are subject to change without notice.*

#### References:

- Bhatt S, Parsa S, Snyder H, et al. Clinical Laboratory Experience with Noninvasive Prenatal Testing: Update on Clinically Relevant Metrics. ISPD 2014 poster.
- Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol.* 2012; 119:890–901.
- Verinata Health, Inc. (2012) Analytical Validation of the veriFi Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18 and 13 and the Option for Classification of Sex Chromosome Status. Redwood City, CA.
- Taneja P et al. Prenatal Diagnosis, Dec 2015.

